- Klíčová slova
- Varilrix, Varivax, Priorix-Tetra,
- MeSH
- atenuované vakcíny aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- dítě MeSH
- lidé MeSH
- očkovací programy ekonomika zákonodárství a právo MeSH
- plané neštovice * epidemiologie komplikace MeSH
- postexpoziční profylaxe metody MeSH
- rizikové faktory MeSH
- séroepidemiologické studie MeSH
- vakcína proti planým neštovicím * dějiny MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
Chřipka byla v České republice často vnímána jako běžné nekomplikované onemocnění. V poslední době zůstala zcela ve stínu nemoci covid-19, ale tato situace se může rychle změnit. Výskyt chřipky stoupá a dochází již běžně k paralelní cirkulaci viru SARS-CoV-2 a influenza virů. Na důležitosti tak opět nabývá očkování proti chřipce, které snižuje riziko nákazy a riziko komplikovaného průběhu. Očkované by měly být především osoby starší 65 let, pacienti s chronickými interními onemocněními (i v dětském věku), těhotné ženy a ti, kdo jsou s rizikovými osobami v kontaktu.
In the Czech Republic, influenza was often perceived as a common uncomplicated illness. Recently, it has been completely overshadowed by the covid-19 disease, but this situation can change quickly. The incidence of influenza is increasing, and parallel circulation of the SARS-CoV-2 virus and influenza viruses is now common. Vaccination against the flu, which reduces the risk of infection and the risk of a complicated course, is becoming more important. People over the age of 65, patients with chronic internal diseases (even in childhood), pregnant women and those who are in contact with risk persons should be vaccinated.
- MeSH
- chřipka lidská * komplikace prevence a kontrola MeSH
- COVID-19 MeSH
- dítě MeSH
- lidé MeSH
- vakcinace MeSH
- vakcíny proti chřipce MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
BACKGROUND: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 years in 2 pivotal efficacy trials (ZOE-50 and ZOE-70). The present interim analysis was performed after ≥2 additional years of follow-up (between 5.1 and 7.1 years [mean] post-vaccination) and includes partial data for year (Y) 8 post-vaccination. METHODS: Annual assessments were performed for efficacy against herpes zoster (HZ) from Y6 post-vaccination and for anti-gE antibody concentrations and gE-specific CD4[2+] T-cell (expressing ≥2 of 4 assessed activation markers) frequencies from Y5 post-vaccination. RESULTS: Of 7413 participants enrolled for the long-term efficacy assessment, 7277 (mean age at vaccination, 67.2 years), 813, and 108 were included in the cohorts evaluating efficacy, humoral immune responses, and cell-mediated immune responses, respectively. Efficacy of RZV against HZ through this interim analysis was 84.0% (95% confidence interval [CI], 75.9-89.8) from the start of this follow-up study and 90.9% (95% CI, 88.2-93.2) from vaccination in ZOE-50/70. Annual vaccine efficacy estimates were >84% for each year since vaccination and remained stable through this interim analysis. Anti-gE antibody geometric mean concentrations and median frequencies of gE-specific CD4[2+] T cells reached a plateau at approximately 6-fold above pre-vaccination levels. CONCLUSIONS: Efficacy against HZ and immune responses to RZV remained high, suggesting that the clinical benefit of RZV in older adults is sustained for at least 7 years post-vaccination. Clinical Trials Registration. NCT02723773.
- MeSH
- adjuvancia imunologická MeSH
- herpes zoster * prevence a kontrola MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- senioři MeSH
- syntetické vakcíny MeSH
- vakcína proti pásovému oparu * MeSH
- virus varicella zoster MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- Publikační typ
- abstrakt z konference MeSH
BACKGROUND: To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents. STUDY DESIGN: This phase 3, open-label study was an extension of 3 phase 2 studies with participants aged 11-18 years randomized to receive primary MenB-FHbp vaccination following 1 of 5 dosing schedules or control. A booster dose was administered 48 months after the primary series. Immunopersistence through 48 months after the last primary dose (persistence stage) and 26 months postbooster (booster stage) was determined by serum bactericidal assays using human complement (hSBAs) against 4 vaccine-heterologous test strains. Safety evaluations included adverse events (AEs) and local and systemic reactions. RESULTS: Overall, 698 and 304 subjects enrolled in the persistence and booster stages, respectively. hSBA titers declined in all groups during 12 months postprimary vaccination, then remained stable through 48 months. One month postbooster, 93.4-100.0% of subjects achieved hSBA titers ≥ lower limit of quantitation against each test strain; percentages at 12 and 26 months postbooster were higher than at similar time points following primary vaccination. Primary and booster MenB-FHbp vaccinations were well tolerated, with ≤ 12.5% of subjects reporting AEs during each stage. The most common local (reported by 84.4-93.8% of subjects) and systemic (68.8-76.6%) reactions to the booster were injection site pain and fatigue and headache, respectively; ≤ 3.7% of subjects reported severe systemic events. CONCLUSION: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease.
- MeSH
- imunogenicita vakcíny MeSH
- lidé MeSH
- meningokokové infekce * prevence a kontrola MeSH
- meningokokové vakcíny * škodlivé účinky MeSH
- mladiství MeSH
- Neisseria meningitidis séroskupiny B * MeSH
- protilátky bakteriální MeSH
- séroskupina MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
